Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase I, open-label, dose-escalation trial of JX-594 (Pexa-Vec) in pediatric
patients with advanced/metastatic, unresectable solid tumors refractory to standard therapy
and/or the patient does not tolerate standard therapies. Tumors are likely to include
neuroblastoma, lymphoma, Wilms' tumor, rhabdomyosarcoma, Ewing's sarcoma, osteosarcoma,
non-rhabdomyosarcoma soft tissue sarcomas, and malignant peripheral nerve sheath tumors.
Benign tumors are excluded. These tumor types were selected because evidence of biological
activity was observed in cancer cells lines and ex vivo infected primary human tissue
samples, specifically pediatric cancer types such as sarcomas and neuroblastomas.